DUODOPA levodopa / carbidopa monohydrate 20mg/mL and 5mg/mL intestinal gel PVC bag Australia - English - Department of Health (Therapeutic Goods Administration)

duodopa levodopa / carbidopa monohydrate 20mg/ml and 5mg/ml intestinal gel pvc bag

abbvie pty ltd - carbidopa monohydrate, quantity: 5 mg/ml; levodopa, quantity: 20 mg/ml - gel - excipient ingredients: purified water; carmellose sodium - for the treatment of advanced idiopathic parkinson?s disease with severe motor fluctuations despite optimised alternative pharmacological treatment.

APO-LEVODOPA/CARBIDOPA 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levodopa/carbidopa 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

APO-LEVODOPA/CARBIDOPA 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-levodopa/carbidopa 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; crospovidone; pregelatinised maize starch; indigo carmine aluminium lake - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

TRIDOPA levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

TRIDOPA levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: magnesium stearate; powdered cellulose; sodium sulfate; hyprolose; microcrystalline cellulose; trehalose dihydrate; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

TRIDOPA levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

tridopa levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

stada pharmaceuticals australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; carmellose sodium; hyprolose; sodium sulfate; magnesium stearate; powdered cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle

medis pharma pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; hyprolose; magnesium stearate; microcrystalline cellulose; sodium sulfate; carmellose sodium; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 125/31.25/200 mg tablet bottle

medis pharma pty ltd - carbidopa monohydrate, quantity: 33.75 mg (equivalent: carbidopa, qty 31.25 mg); entacapone, quantity: 200 mg; levodopa, quantity: 125 mg - tablet, film coated - excipient ingredients: trehalose dihydrate; microcrystalline cellulose; hyprolose; magnesium stearate; powdered cellulose; carmellose sodium; sodium sulfate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; hyprolose; carmellose sodium; microcrystalline cellulose; magnesium stearate; trehalose dihydrate; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: powdered cellulose; microcrystalline cellulose; sodium sulfate; carmellose sodium; magnesium stearate; hyprolose; trehalose dihydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.